The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

被引：0
|
作者：
Hollaender, Norbert [1 ]
Glimm, Ekkehard [1 ]
Gauvin, Jennifer [2 ]
Stefanelli, Tommaso [1 ]
Zeiser, Robert [3 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Freiburg, Fac Med, Med Ctr, Dept Med 1, Freiburg, Germany
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10521 / 10522
页数：2
相关论文
共 50 条
  • [31] MANAGEMENT OF CORTICOSTEROIDS IN PATIENTS RECEIVING RUXOLITINIB TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: A POST HOC ANALYSIS FROM THE RANDOMIZED PHASE 3 REACH3 STUDY
    Kintsch, Emily
    Xue, Zhenyi
    Galvin, John
    Locatelli, Franco
    Zeiser, Robert
    Bhatt, Valkal
    BONE MARROW TRANSPLANTATION, 2024, 59 : 310 - 310
  • [32] Long-Term Follow-up of Ruxolitinib in Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (GVHD)
    Ferreira, Aliana Meneses
    Molla, Vinicius Campos
    Seiwald, Maria Cristina Nunez
    Szor, Roberta Shcolnik
    De Moraes, Pedro Henrique Arruda
    Da Fonseca, Ana Rita
    Serpa, Mariana
    Xavier, Erick Menezes
    Tucunduva, Luciana
    Novis, Yana
    Arrais-Rodrigues, Celso
    BLOOD, 2020, 136
  • [33] Efficacy of extracorporeal photopheresis in chronic cutaneous graft-versus-host disease: a retrospective study
    Alband, N.
    Saglam, S.
    Basu, T. N.
    Child, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 : 31 - 32
  • [34] Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study
    Escamilla Gomez, Virginia
    Garcia Gutierrez, Valentin
    Astibia Mahillo, Beatriz
    Alcalde, Patricia
    Lopez Corral, Lucia
    Acera Gomez, Marina
    Torres, Melissa
    Borrego Borrego, Asuncion
    Gonzalez Pinedo, Leslie
    Zudaire, Maite
    Gonzalez Vicent, Marta
    Benzaquen, Ana
    Izquierdo Garcia, Isabel
    Asensi, Pedro
    Montoro Gomez, Juan
    Orti Pascual, Guillermo
    Valcarcel, David
    Benitez Carabante, Maria Isabel
    de Heredia Rubio, Cristina Diaz
    Canamero Giro, Eloi
    Ferra, Christelle
    Garcia-Cadenas, Irene
    Redondo, Sara
    Sisinni, Luisa
    Perez, Antonio
    Mussetti, Alberto
    Garcia, Lucia
    Palomo Moraleda, Maria Del Pilar
    Gonzalez Sierra, Pedro Antonio
    Jurado Chacon, Manuel
    Perez-Simon, Jose A.
    BLOOD, 2022, 140 : 7754 - 7756
  • [35] Ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease: a comparison of response by organ class from the randomized, phase 3 REACH2 study
    Mohty, M.
    Zeiser, R.
    Galvin, J.
    Wilke, C.
    Tian, C.
    Bhatt, V.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 39 - 40
  • [36] Ruxolitinib Versus Best Available Therapy in Patients With Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 6 - 7
  • [37] The impact of COVID-19 and ruxolitinib on extracorporeal photopheresis in chronic graft-versus-host disease: a retrospective observational study
    Mathew, Libin
    Saglam, Sukran
    Child, Fiona
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 110 - 111
  • [38] The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
    Srinagesh, Hrishikesh
    Ozbek, Umut
    Kapoor, Urvi
    Ayuk, Francis Ayuketang
    Aziz, Mina D.
    Ben-David, Kaitlyn
    Choe, Hannah K.
    Defilipp, Zachariah
    Etra, Aaron
    Grupp, Stephan
    Hartwell, Matthew
    Hexner, Elizabeth O.
    Hogan, William J.
    Kitko, Carrie
    Kowalyk, Steven
    Lin, Jung-Yi
    Major-Monfried, Hannah
    Mielke, Stephan
    Merli, Pietro
    Morales, George
    Ordemann, Rainer
    Pulsipher, Michael A.
    Qayed, Muna
    Reddy, Pavan
    Reshef, Ran
    Roesler, Wolf
    Sandhu, Karamjeet S.
    Schechter-Finkelstein, Tal
    Shah, Jay
    Sigel, Keith
    Weber, Daniela
    Wolfl, Matthias
    Wudhikarn, Kitsada
    Young, Rachel
    Levine, John E.
    Ferrara, James L. M.
    BLOOD, 2019, 134
  • [39] Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges
    Redondo, Sara
    Esquirol, Albert
    Novelli, Silvana
    Carolina Caballero, Ana
    Garrido, Ana
    Onate, Guadalupe
    Lopez, Jordi
    Moreno, Carol
    Saavedra, Silvanna-Daniela
    Granell, Miquel
    Briones, Javier
    Sierra, Jorge
    Martino, Rodrigo
    Garcia-Cadenas, Irene
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (01): : 43.e1 - 43.e5
  • [40] Efficacy and Toxicity of Ruxolitinib in Patients with steroid-resistant Acute and Chronic graft-versus-host Disease after Hematopoietic Cell Transplantation
    Petropoulou, Anna
    Nabergoj, Mitja
    Mamez, Anne-Claire
    Morin, Sarah
    Mahne, Elif
    Ortiz, Carmen De Ramon
    Stephan, Caroline
    Ayer, Christian
    Bruno, Benjamin
    Bounaix, Laura
    Anastasiou, Maria
    Mappoura, Maria
    Dantin, Carole
    Beauverd, Yan
    Simonetta, Federico
    Giannotti, Federica
    Masouridi-Levrat, Stavroula
    Chalandon, Yves
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 334 - 335
12345